Abstract: Provided herein are compounds of formula (1): or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein X1, X2, Ry, Rz, R1, R2, R3, and R4 are as defined herein. Also provided herein is a pharmaceutically acceptable composition comprising a compound of formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing. Also provided herein are methods of using a compound of formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, to treat various diseases, disorders, and conditions responsive to the modulation of the contractility of the skeletal sarcomere.

Abstract: A charging-control circuit, connecting an in-vehicle apparatus with an external apparatus and enabling data-transfer therebetween, includes a DC-to-DC converter, to which a main power-supply's battery-voltage or the in-vehicle apparatus's bus-voltage is supplied, converting the supplied voltage to a predetermined voltage; an output controller controlling the data-transfer, and determining a current for the external apparatus; and an instantaneous-interruption measurement-circuit, preventing the data-transfer's instantaneous-interruption when the battery-voltage drops to below the predetermined voltage, including a first switch switching between supply and cut-off from the bus-voltage to the converter according to the battery-voltage, a resistor, connected between an output terminal to the external apparatus and the output controller, limiting an output current flowing to the output terminal, and a second switch, connected in parallel with the resistor and connected in series with the first switch, causing a c

Abstract: An object is to obtain a carriage for a hard disk driving actuator by a cheap cost in which an attaching intensity of the bearing can be sufficiently enhanced. Also, an object is to obtain a carriage plate in which it is possible to align a position for a plurality of carriage plates highly accurately with a high rigidity and a thin thickness and it is possible to enhance an attaching intensity to the bearing sufficiently. A carriage formed by a pressing operation by a press comprises a fixed bearing section, a fixed coil section, and an arm section. The thickness of the fixed bearing section is thicker than the thickness of the arm section and the fixed coil section. The rigidity in the arm section and the fixed coil section are higher than the rigidity in the fixed bearing section. It is acceptable if a plurality of longitudinal grooves which extend in an axial direction are formed on an inner wall of an attaching hole for the fixed bearing section so as to enhance the attaching accuracy of the bearing.

Abstract: The present invention relates to phenylethanolamine compounds represented by general formula [I]: ##STR1## (where R.sub.1 represents hydrogen or halogen; R.sub.2 represents hydrogen, hydroxy, lower alkoxy, lower alkoxy substituted with one or two lower alkoxycarbonyl or carboxy groups, lower alkoxy substituted with lower alkylaminocarbonyl which may be substituted with lower alkoxy, lower alkoxy substituted with cyclic aminocarbonyl of 4 to 6 carbon atoms, lower alkoxycarbonyl or carboxy; R.sub.3 represents hydrogen, hydroxy, lower alkoxy or lower alkoxy substituted with one or two lower alkoxycarbonyl or carboxy groups; R.sub.2 and R.sub.3 may be bonded to each other to form methylenedioxy substituted with carboxy or lower alkoxycarbonyl; and m and n are 0 or 1), and their pharmacologically acceptable salts, which have a potent .beta.3 adrenergic stimulating effect and high .beta.3 adrenergic receptor selectivity, as well as to processes for their production and intermediates in their production.

Abstract: Novel 1,4-dihydropyridine derivatives of the formula [I] are provided: ##STR1## wherein R.sup.1 represents a C.sub.1-4 alkyl group or a C.sub.3-6 alkoxyalkyl group, R.sup.2 represents hydrogen or halogen, R.sup.3 is either nitro when R.sup.2 is hydrogen, or halogen when R.sup.2 is halogen, R.sup.4 represents a pyridyl group, a phenethyl group, an unsubstituted benzyl group, a substituted benzyl group having one or more suitable substituents, an unsubstituted phenyl group, or a substituted phenyl group having one or more suitable substituents, and A represents an unsubstituted hexamethylene group or a substituted hexamethylene group having one or two C.sub.1-3 alkyl groups. The 1,4-dihydropyridine derivatives have vasodilating and hypotensive activity which is kept for a long period, and are useful in the treatment of cardiovascular disease and hypertension.